Shopping Cart
Remove All
Your shopping cart is currently empty
Suvizumab (Synonyms: KD-247)
Catalog No. T76991 Copy Product Info
🥰Excellent
Suvizumab (KD-247) is a humanized monoclonal neutralizing antibody targeting the V3 loop of the HIV-1 envelope glycoprotein gp120. This product specifically binds to the V3 domain of gp120, effectively neutralizing various HIV-1 strains (e.g., MN, SF2, and 89.6) and blocking virus-host cell fusion. Suvizumab reduces viral load and is well-tolerated, serving as an important pharmacological tool for researching HIV prevention, passive immunotherapy, and viral immune escape mechanisms.
Suvizumab
Copy Product Info🥰Excellent
Catalog No. T76991
Synonyms KD-247
Suvizumab (KD-247) is a humanized monoclonal neutralizing antibody targeting the V3 loop of the HIV-1 envelope glycoprotein gp120. This product specifically binds to the V3 domain of gp120, effectively neutralizing various HIV-1 strains (e.g., MN, SF2, and 89.6) and blocking virus-host cell fusion. Suvizumab reduces viral load and is well-tolerated, serving as an important pharmacological tool for researching HIV prevention, passive immunotherapy, and viral immune escape mechanisms.
Suvizumab
Cas No. 914257-21-9
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $697 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $1,080 | 2-4 weeks | 2-4 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Suvizumab (KD-247) is a humanized monoclonal neutralizing antibody targeting the V3 loop of the HIV-1 envelope glycoprotein gp120. This product specifically binds to the V3 domain of gp120, effectively neutralizing various HIV-1 strains (e.g., MN, SF2, and 89.6) and blocking virus-host cell fusion. Suvizumab reduces viral load and is well-tolerated, serving as an important pharmacological tool for researching HIV prevention, passive immunotherapy, and viral immune escape mechanisms. |
| Targets&IC50 | HIV-1 SF2:1.0 μg/mL, HIV-1 MN:0.1 µg/mL, HIV-1 89.6:0.2 µg/mL |
| In vitro | In neutralization assays, Suvizumab (KD-247) demonstrates potent activity against multiple HIV-1 strains, with IC50 values of 0.1 µg/mL for HIV-1MN, 0.2 µg/mL for HIV-189.6, and 1.0 µg/mL for HIV-1SF2; however, the antibody shows significant resistance to pseudoviruses carrying the G314E mutation within the V3 loop [2][3]. |
| In vivo | In pharmacological studies using cynomolgus macaque models infected with SHIV C2/1, intravenous administration of Suvizumab (15, 30, and 45 mg/kg) dose-dependently reduced plasma viremia and increased CD4+ T-cell counts; furthermore, repeated weekly doses (45 mg/kg) for two months significantly mitigated the loss of CD4+ T cells in lymphoid tissues and provided sterile protection against viral challenge [2][4]. |
| Synonyms | KD-247 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | HIV-1 MN/HIV-1 SF2/HIV-1 89.6 |
| Cas No. | 914257-21-9 |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Suvizumab | purchase Suvizumab | Suvizumab cost | order Suvizumab | Suvizumab in vivo | Suvizumab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.